Transforming Trauma Care with
Our Mission & Vision
Vision:
To redefine trauma care and emergency response by providing life-saving blood replacement solutions that extend survival and improve outcomes in critical situations, anywhere in the world.
Mission:
Our mission at HemoGuard is to pioneer innovative blood replacement technology that bridges the gap in emergency care, delivering safe, universally compatible, and stable blood substitutes. We are committed to empowering medical professionals with dependable solutions that enhance patient survival in extreme conditions, from remote locations to military fields and hospitals, ensuring that timely, life-sustaining support is always within reach.
We are 100% committed to advancing life-saving blood replacement technology that delivers safe, effective, and universally compatible solutions for critical care. Our dedication lies in providing medical professionals with the tools they need to stabilize patients in life-threatening situations, extending survival time in environments where traditional blood supplies are inaccessible. Through rigorous research, innovation, and quality assurance, we strive to set the highest standard in emergency trauma care, ensuring every product we develop upholds our promise to save lives in extreme conditions.
We are dedicated to delivering billions of liters of our life-saving blood replacement solution worldwide. Our goal is to make this critical resource universally available in environments where traditional blood supplies are scarce or unavailable, such as remote regions, military fields, emergency response sites, space missions, and disaster-stricken areas. By scaling production to meet the needs of global trauma and emergency care, we aim to transform survival outcomes, providing healthcare providers with an essential tool to stabilize patients and extend life when every second counts.
Our team is led by experienced scientists and biotech innovators with deep expertise in emergency medicine, biotechnology, and trauma care solutions. The team combines decades of research in blood substitute technology, bioengineering, and the development of bioidentical compounds, making them exceptionally qualified to advance HemoGuard’s life-saving potential. Our experts understand the complex requirements of emergency and military medicine, and they apply proprietary knowledge in encapsulation, oxygen delivery, and immune compatibility to ensure our product is safe, effective, and universally compatible.
This unique blend of skills and experience positions our team to meet the demands of critical care in extreme environments, allowing us to bring a stable, reliable blood replacement solution to those who need it most—whether on the battlefield, in remote areas, or in emergency response settings.
To bring HemoGuard to market as a reliable, life-saving blood replacement solution, we’re advancing several core projects focused on safety, functionality, and scalability:
- Oxygen Delivery Optimization: Nano-encapsulated hemoglobin ensures controlled, sustained oxygen release to vital organs during trauma.
- Universal Compatibility Testing: Validates compatibility across all blood types, allowing rapid administration in emergencies.
- Extended Stability and Shelf Life: Developed for extreme conditions with a shelf life of over 18 months at room temperature.
- Clotting Support with Fibroblast Growth Factors: Supports hemostasis and reduces excessive bleeding risks in trauma patients.
- Antioxidant Integration: Neutralizes oxidative stress, ensuring safety and efficacy during prolonged use.
- Regulatory and Clinical Trials: Focused on achieving regulatory approval through rigorous testing.
- Scalable Manufacturing: Built to meet global demand, producing billions of liters while maintaining product quality.
These projects are essential to making HemoGuard an accessible, dependable option for critical care in diverse environments.
Revolutionary Blood Substitute Technology
Molecular Stability
Battlefield Application
Efficacy
Exploring the Market Potential
The global market for blood substitutes is expected to grow exponentially, driven by the increasing demand for safe and effective alternatives to traditional blood transfusions. HemoGuard-Safe is poised to capture a significant share of this market. Valuations for companies developing artificial blood substitutes can vary significantly depending on factors such as their development stage, market potential, and regulatory progress. Here are some relevant examples from the industry that may provide a benchmark for assessing VivoVac’s potential worth:
KaloCyte – This U.S.-based startup is working on ErythroMer, a freeze-dried, nanoparticle-encapsulated synthetic red blood substitute. KaloCyte secured $373,000 in NIH grants and additional venture funds, indicating the funding landscape for preclinical-stage companies like VivoVac【42】.
Hemoglobin Oxygen Therapeutics LLC – Known for developing Hemopure, this company focuses on oxygen-carrying substitutes for both human and veterinary use. Although specific valuation figures aren’t disclosed, companies at this stage often attract multi-million-dollar investments from defense or healthcare partners for trauma-related solutions【40】.
NuvOx Pharma – This company develops oxygen therapeutics to treat hypoxic conditions. It has received both public and private funding, demonstrating investor interest in innovative solutions addressing trauma care and oxygen delivery challenges, which aligns with VivoVac’s product goals【41】.
The artificial blood substitutes market itself is expected to grow significantly, projected to reach $24.08 billion by 2029, driven by rising demand for trauma care solutions and shortages of donor blood【42】. Such forecasts underscore the potential value of innovative products like HemoGuard-Safe™ in military and emergency applications.
- Projected market growth of 5% annually
- Increasing demand in military and emergency medical sectors
- Potential to save thousands of lives annually
Investment Opportunities with HemoGuard-Safe
- Groundbreaking technology with significant market potential
- Proven product efficacy in critical environments
- Strong commitment to saving lives and improving trauma care
Strategic Military and Civilian Applications
HemoGuard-Safe aims to partner with leading military organizations upon completion of our initial and Phase 2 trials to revolutionize trauma care on the battlefield. Our innovative blood replacement solution is designed to save lives in extreme conditions, offering a safe, effective alternative to traditional blood transfusions where resources are limited..
Transforming Trauma Care: Life-Saving Innovation for Extreme Conditions
Our mission at HemoGuard is to revolutionize trauma care by providing a dependable, universally compatible blood replacement solution that extends survival in critical emergencies. We are dedicated to empowering medical professionals with life-saving technology that bridges gaps in care for patients in remote locations, military settings, and emergency response situations. Through relentless innovation, rigorous safety standards, and a commitment to accessibility, we aim to set a new standard in emergency medicine, ensuring every patient has a chance at survival when traditional blood supplies are unavailable.
Our Partners
To bring HemoGuard to those who need it most, we will partner with leading organizations across military, healthcare, and humanitarian sectors. Collaborations with defense agencies, hospitals, emergency services, and global health organizations will enable us to deploy life-saving blood replacement solutions in critical settings. Future partnerships with academic and research institutions will help advance our technology, while cooperation with regulatory bodies ensures the highest standards of safety and efficacy. Together, we are redefining trauma care worldwide.